Many other molecular targeted drugs, including tyrosine kinase inhibitors, Bruton kinase inhibitors, PI3k inhibitors, BCL2 inhibitors, JAK inhibitors, and checkpoint inhibitors, demonstrated in vitro and in vivo synergistic activity with CAR T-cells in various settings, and they can also potentially be used in AML. The gene discussed is BCL2; the disease is acute myeloid leukemia.